A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
The purpose of this study is to provide the option of brentuximab vedotin treatment to patients randomly allocated to placebo treatment in the Phase 3 study SGN35-005 that experienced disease progression of HL. Additionally in the US only, the purpose of this study is to provide access to brentuximab vedotin for patients with relapsed or refractory HL or patients with relapsed or refractory systemic ALCL who have previously failed frontline chemotherapy.
Lymphoma, Large-Cell, Anaplastic
Drug: brentuximab vedotin
|Study Type:||Expanded Access What is Expanded Access?|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01196208
Show 23 Study Locations
|Study Director:||Laurie Grove, PA-C||Seattle Genetics, Inc.|